Lung cancer survivorship: recurrence risk, second primaries and chemoprevention

DAY 3

Chaired by: Dr Liz Fuller (Newcastle) and Dr Alexandra Teagle (Plymouth)

3:30 pm	Expanding roles of liquid biopsies for lung cancer: detection, residual disease, surveillance and beyond Professor Nitzan Rosenfeld (London)
4:00 pm	Second primary lung cancers – who is at risk and how long should we follow people up? Professor Robert Rintoul (Cambridge)
4:30 pm	Preventing the next tumour: are vaccines the answer? Professor Mariam Jamal-Hanjani (London)

3:30 PM

90 MINUTE SESSION

Learning objectives

To recognise the risk of second primary lung cancers in radically treated patients, appreciate potential factors associated with increased risk and be aware of future tools for risk assessment and early detection.
To understand the concept of minimal residual disease in lung cancer, its relationship with recurrence and biomarkers to aid surveillance and early diagnosis.
To describe current and emerging chemoprevention strategies with a focus on vaccine therapy to prevent or delay the development of second primary lung cancers and tumour recurrence after radical treatment.